Alzheimer's Drug Shows Early Promise

By Amanda Gardner HealthDay Reporter FRIDAY, June 27 (HealthDay News) -- Long-anticipated results from a trial on an experimental Alzheimer's therapy look promising, at least in a certain group of patients. Findings that are slated to be presented Sunday at the International Conference on Alzheimer's Disease in Chicago suggest that while the drug, bapineuzumab, showed only a modest trend towards a benefit in patients with the ApoE4 gene, there were more notable improvements in the degree of cognitive decline in individuals lacking the gene.